Tuesday, June 30, 2015

Sanofi buys Rolaids from J&J's McNeil Consumer Healthcare unit

Sanofi said Monday it bought Rolaids antacid brand products from the McNeil Consumer Healthcare Unit of Johnson & Johnson.

Sanofi buys Rolaids from J&J's McNeil Consumer Healthcare unit

0 comments

Sanofi said Monday it bought Rolaids antacid brand products from the McNeil Consumer Healthcare Unit of Johnson & Johnson.

The company did not reveal a price in its Monday morning announcement.

McNeil Consumer Healthcare is based in Fort Washington, Montgomery County, and is under the umbrella of McNeil, PPC, which is part of J&J's consumer branch.

Sanofi aventis is based in Paris and is one of the world's largest pharmaceutical companies. Sanofi's Chattem division, based in Chattanooga, Tenn., will take over selling Rolaids. Sanofi has facilities in New Jersey and Pennsylvania.

"The addition of Rolaids represents a rare opportunity to obtain an iconic brand that we believe will respond positively to our proven approach of growing brands through innovation and advertising," Zan Guerry, chief executive officer of Chattem said in a statement. "We are primed to leverage the Rolaids market opportunity to drive incremental growth and take the brand to a new level."

In late December, the Federal Trade Commission approved the sale, thought the companies declined to say at that time what products were changing hands.

 

 

0 comments
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy:

Philly.com comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by Philly.com staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
 
comments powered by Disqus
About this blog
David Sell blogs about the region's pharmaceutical industry. Follow him on Facebook.

For Inquirer.com. Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Reach David at dsell@phillynews.com.

David Sell
Also on Philly.com:
letter icon Newsletter